[{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bill & Melinda Gates Foundation","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"Bill & Melinda Gates Foundation \/ The Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Bill & Melinda Gates Foundation \/ The Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Antiviral drug","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subdermal Implant","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Inventprise","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"IVT-25","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Atreca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"ATRC-501","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Medical Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Medical Research Institute"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Gritstone bio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Self-Amplifying mRNA Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Anti-CSP IgM Antibodies","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Vaccinal Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bill & Melinda Gates Foundation","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"AR-701","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Providence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"PTX-COVID19-B","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"OPC-167832","moa":"DprE1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Bactolife","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Nuvisan GmbH","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"MK-7762","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"DARE-LBT","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Vaxart","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"Norovirus Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"DelSiTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"SpyBiotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Osivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OVX836","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Smart Immune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Allogeneic T-cell Progenitor","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"VIR-1388","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Aegis Life","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"DNA-encoded Monoclonal Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"AS01E","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0.55000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.55000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Medroxyprogesterone Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Delamanid","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"VitriVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Sail Biomedicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Aegis Life","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"MTBVAC","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bill & Melinda Gates Foundation","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Radiant Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Surf Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"SNIPR Biome","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Radiant Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bill & Melinda Gates Foundation","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Chemify","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Immorna","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"JCXH-108","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"5","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"PopVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Ferrous Gluconate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Insud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SPAIN","productType":"Peptide","year":"2024","type":"Funding","leadProduct":"Oxytocin","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Monoclonal Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"VitriVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Hexavalent Polio Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Tessera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Micron Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"MRV-MNP","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Ethris","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Funding","leadProduct":"ETH47","moa":"SARS-CoV-2 spike protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"}]

Find Clinical Drug Pipeline Developments & Deals by Bill & Melinda Gates Foundation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : The grant will support Micron’s efforts in increasing access to measles-rubella vaccine, MRV-MNP, and the ongoing manufacturing scale-up efforts and activities to support a phase 2 trial in infants.

                          Product Name : MRV-MNP

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 07, 2025

                          Lead Product(s) : MRV-MNP

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Micron Biomedical

                          Deal Size : $43.0 million

                          Deal Type : Funding

                          blank

                          02

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : The funding will be used to support the development of Tessera's in vivo program for sickle cell disease program into the clinic.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 18, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Hematology

                          Highest Development Status : Preclinical

                          Recipient : Tessera Therapeutics

                          Deal Size : $50.0 million

                          Deal Type : Funding

                          blank

                          03

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : The funding will help VitriVax to applying its proprietary ALTA technology to new polio vaccine candidates composed of virus-like particles (VLPs) for use in future combination hexavalent vaccines.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 04, 2024

                          Lead Product(s) : Hexavalent Polio Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Recipient : VitriVax

                          Deal Size : $3.6 million

                          Deal Type : Funding

                          blank

                          04

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : The proceeds will be used for the launch of a Phase II Clinical Trial to determine the optimal dose of an innovative sublingual oxytocin treatment designed to prevent postpartum hemorrhage.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          November 21, 2024

                          Lead Product(s) : Oxytocin

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Preclinical

                          Recipient : Insud Pharma

                          Deal Size : $2.7 million

                          Deal Type : Funding

                          blank

                          05

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : The proceeds will be used to develop cost-effective monoclonal antibodies for RSV and malaria using C1 platform technology.

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 21, 2024

                          Lead Product(s) : Monoclonal Antibody

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : Dyadic International, Inc

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          06

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : The proceeds will fund the development to accelerate the ongoing Ovaprene (ferrous gluconate & ascorbic acid), a novel, hormone-free monthly intravaginal contraceptive, pivotal study.

                          Product Name : Ovaprene

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 13, 2024

                          Lead Product(s) : Ferrous Gluconate,Ascorbic Acid

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase III

                          Recipient : Daré Bioscience

                          Deal Size : $10.7 million

                          Deal Type : Funding

                          blank

                          07

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : The proceeds will be used to develop novel thermostable delivery formulations for mRNA-based vaccines and therapeutics.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          October 30, 2024

                          Lead Product(s) : mRNA-based Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : PopVax

                          Deal Size : $1.1 million

                          Deal Type : Funding

                          blank

                          08

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : The funding will aims to support the company to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 17, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Recipient : AN2 Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          09

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : The funding will support the efficient design and synthesis of novel small molecules for treating TB and malaria by leveraging the company’s proprietary Chemputation technology and workflow.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 01, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Recipient : Chemify

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          10

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : This financing will enable the next stage in Radiant’s growth and move the company toward the clinic, Multabody platform against therapeutic targets that cannot be treated with traditional antibodies.

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 11, 2024

                          Lead Product(s) : Antibody-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Recipient : Radiant Biotherapeutics

                          Deal Size : $35.0 million

                          Deal Type : Series A Financing

                          blank